ELEKTA SELECTED BY CANADIAN WORLD LEADER IN CANCER TREATMENT

PRESS RELEASE Stockholm, Sweden, May 27, 2005 Princess Margaret Hospital will ensure highest quality cancer treatments with new IGRT and SRT systems from Elekta

Princess Margaret Hospital (PMH) in Toronto will enhance its leadership in image-guided radiation therapy (IGRT) with the addition of an Elekta Synergy® system. PMH will also build on its stereotactic expertise by installing Canada’s first Elekta Synergy® S – a radiation delivery system optimized for advanced stereotactic radiation therapy (SRT).

“Elekta Synergy® brings together three key elements that are major developments for cancer care: reduced risk of side-effects, potential for dose escalation and efficient delivery of care. This is something that benefits the patient, the physician wants, and is needed in the healthcare system,” says Mary Gospodarowicz, MD, FRCPC, Chief of Radiation Oncology, Princess Margaret Hospital.

Princess Margaret Hospital, a teaching hospital of the University of Toronto, has achieved an international reputation as a global leader in the fight against cancer. Specializing in cancer research, treatment and education, PMH sees about 190,000 outpatients annually for diagnosis, treatment and follow-up.

By imaging patients in the treatment position during the actual time of treatment, clinicians using Elekta Synergy® are able to deliver the intended radiation dose to a target with significantly more confidence. For the first time, radiation oncologists have real-time 3-D image information and the most precise treatment delivery, all from the same system. Between and during treatment sessions, patients’ internal organ movement can shift the position of the cancer tumor, compromising the effectiveness of the radiation treatment. With online imaging, the beam can be positioned more accurately prior to and during radiation treatment delivery.

“Princess Margaret Hospital is one of four hospitals instrumental in the clinical development of the Elekta Synergy® image guided platform, and is currently a member of the Elekta Synergy® Research Group,” said Mark Symons, General Manager for Elekta, Canada, Inc. “By doubling the number of Elekta Synergy® units, PMH confirming that image-guided technology is relevant for North America and it contributes to more effective cancer treatment.”

The stereotactic features of the Elekta Synergy® S extend the image-guided capability of the Elekta Synergy® system, offering exciting new possibilities for treating small tumors close to critical structures. The system includes Elekta’s innovative Beam Modulator™, an integrated, high-resolution, multi-leaf collimator designed to be used on surgical sites outside the brain, such as cancers of the spine, liver, neck, prostate, pancreas and lung.

“Lung cancer, as well as cancers along the spine, have always been difficult sites to treat for cancer due to respiratory motion and the proximity of critical organs,” says David Jaffray PhD, Head of Radiation Physics, Princess Margaret Hospital. “The improved accuracy provided by Elekta Synergy® S will allow us to offer patients new hope in treating these difficult-to-treat cancers.”

********